Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors
Tóm tắt
Từ khóa
Tài liệu tham khảo
Druker BJ et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408–2417
Shah NP et al (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2):117–125
Gorre ME et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531):876–880
Jabbour E et al (2007) Current and emerging treatment options in chronic myeloid leukemia. Cancer 109(11):2171–2181
Kantarjian HM et al (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145(12):913–923
Kantarjian H et al (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109(12):5143–5150
Talpaz M et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24):2531–2541
Shah NP et al (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682):399–401
Nam S et al (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65(20):9185–9189
Hochhaus A et al (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109(6):2303–2309
Shah NP et al (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26(19):3204–3212
Quintas-Cardama A et al (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25(25):3908–3914
Kantarjian HM et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10):3540–3546
Bergeron A et al (2007) Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 176(8):814–818
de Lavallade H et al (2008) Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 141(5):745–747
Kim D et al (2008) Pleural effusion in dasatinib-treated chronic myeloid leukemia patients after imatinib failure. ASH Annual Meeting Abstracts 112(11):4270
Cortes J et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22(12):2176–2183
Posadas EM et al (2007) A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 110(2):309–317
Lombardo LJ et al (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47(27):6658–6661
Buchdunger E et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139–145
Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79(4):1283–1316
Lindahl P et al (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277(5323):242–245
Jayson GC et al (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23(5):973–981
Wilhelm SM et al (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7(10):3129–3140
Strumberg D et al (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12(4):426–437
Laird AD et al (2002) SU6668 inhibits Flk-1/KDR and PDGFR{beta} in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 16(7):681–690
Wallez Y et al (2007) Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene 26(7):1067–1077
Luton F et al (1999) The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo. Mol Cell 4(4):627–632
Rix U et al (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110(12):4055–4063
Matsuyama W et al (2005) Involvement of discoidin domain receptor 1 in the deterioration of pulmonary sarcoidosis. Am J Respir Cell Mol Biol 33(6):565–573
Sakamoto O et al (2001) Expression of discoidin domain receptor 1 tyrosine kinase on the human bronchial epithelium. Eur Respir J 17(5):969–974
Berg LJ et al (2005) Tec family kinases in T lymphocyte development and function. Annu Rev Immunol 23:549–600
Lindvall JM et al (2005) Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 203:200–215
Kawakami Y et al (1999) Functions of Bruton's tyrosine kinase in mast and B cells. J Leukoc Biol 65(3):286–290
Mustjoki S et al (2008) Clonal expansion of T/NK-Cells during tyrosine kinase inhibitor dasatinib therapy. ASH Annual Meeting Abstracts 112(11):573
Mustjoki S et al (2007) Clonal large granular lymphocyte (LGL) expansion associated with dasatinib therapy. ASH Annual Meeting Abstracts 110(11):2938
Druker BJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031–1037
le Coutre PD, 11 et al (2008) Occurrence of pleural/pericardial effusions in Ph + CML patients failing prior tyrosine kinase inhibitors (TKI) before starting nilotinib—retrospective analysis upon entry into the nilotinib compassionate use program. ASH Annual Meeting Abstracts 112:4271
Breccia M et al (2005) Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. Eur J Haematol 74(1):89–90
Barton JC et al (2002) Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia. Am J Hematol 71(2):139–140
Hazarika M et al (2008) Tasigna for chronic and accelerated phase Philadelphia chromosome—positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14(17):5325–5331
Weisberg E et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2):129–141
Puttini M et al (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl + neoplastic cells. Cancer Res 66(23):11314–11322
Cortes J et al (2008) Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph + chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib. ASH Annual Meeting Abstracts 112(11):1098
Hochhaus A et al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22(6):1200–1206
Cortes J et al (2008) Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). ASH Annual Meeting Abstracts 112(11):182
Rosti G et al (2008) High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase II trial of the GIMEMA CML Working Party. ASH Annual Meeting Abstracts 112(11):181
Stephens J et al (2007) The cost of managing pleural effusion associated with dasatinib in CML patients post imatinib failure. ASH Annual Meeting Abstracts 110(11):4586
Hu Y et al (2004) Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 36(5):453–461
Cortes J et al (2006) Dasatinib (SPRYCEL®) in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP). ASH Annual Meeting Abstracts 108(11):2161